Top 20 of Prostatic Neoplasms

Article title # Publications/# Citations

Circulating microRNAs as stable blood-based markers for cancer detection.

2008: AAllen; CWDrescher; BRFritz; RGentleman; BSKnudsen; EMKroh; DWLin; DBMartin; ... PSMitchell; PSNelson; JNoteboom; KCO'Briant; RKParkin; APeterson; ELPogosova-Agadjanyan; DLStirewalt; MTewari; NUrban; RLVessella; SKWyman;

735

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

2005: XCao; AMChinnaiyan; SMDhanasekaran; RKuefer; CLee; RMehra; JEMontie; SPerner; ... KJPienta; DRRhodes; MARubin; RBShah; XWSun; JTchinda; SATomlins; SVarambally;

734

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

1997: SHBigner; SBose; BCGiovanella; HHibshoosh; MIttmann; JLi; DLiaw; RMcCombie; ... CMiliaresis; RParsons; KPodsypanina; JPuc; LRodgers; BTycko; SIWang; MHWigler; CYen;

727

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

1996: FEHarrell; KLLee; DBMark;

714

Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

2000: KHemminki; NVHolm; AIliadou; JKaprio; MKoskenvuo; PLichtenstein; EPukkala; ASkytthe; PKVerkasalo;

534

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

2004: TAX 327 Investigators; WRBerry; KNChi; Rde Wit; MAEisenberger; JHorti; NDJames; SOudard; ... APluzanska; MARosenthal; IFTannock; CTheodore; ITuresson;

527

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

2012: SAgrawal; RAAnders; SJAntonia; MBAtkins; JRBrahmer; RDCarvajal; LChen; CGDrake; ... SNGettinger; AGupta; FSHodi; LHorn; MJure-Kunkel; GDKollia; AJKorman; PDLeming; DFMcDermott; DMcDonald; TLMcMiller; DMPardoll; JDPowderly; WHSharfman; DCSmith; JASosman; DRSpigel; MSznol; JMTaube; SLTopalian; JMWigginton; HXu;

504

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

2010: IMPACT Study Investigators; ERBerger; RDreicer; ACFerrari; MWFrohlich; CSHigano; PWKantoff; DFPenson; ... CHRedfern; PFSchellhammer; NDShore; RBSims; EJSmall; YXu;

486

The Ki-67 protein: from the known and the unknown.

2000: JGerdes; TScholzen;

482

Integrative genomic profiling of human prostate cancer.

2010: YAntipin; VKArora; BSCarver; ECerami; IDolgalev; JAEastham; WLGerald; AGopalan; ... AHeguy; HHieronymus; PKaushik; TLanders; AELash; JEMajor; NMitsiades; VEReuter; BReva; CSander; CLSawyers; PTScardino; HIScher; NSchultz; NDSocci; BSTaylor; MWilson; YXiao;

481

Screening and prostate-cancer mortality in a randomized European study.

2009: ERSPC Investigators; GAus; AAuvinen; CHBangma; ABerenguer; BGBlijenberg; SCiatto; HJde Koning; ... LJDenis; JHugosson; MKwiatkowski; HLilja; MLujan; LMäättänen; SMMoss; VNelen; XRebillard; FRecker; MJRoobol; FHSchröder; TLTammela; Tvan der Kwast; AVillers; MZappa;

453

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

2005: ZChen; CCordon-Cardo; ZADotan; WGerald; JAKoutcher; HKLin; TLudwig; MNiki; ... PPPandolfi; HIScher; DShaffer; LCTrotman;

437

Molecular determinants of resistance to antiandrogen therapy.

2003: SHBaek; CDChen; RChen; MGRosenfeld; CLSawyers; CTran; RVessella; DSWelsbie;

436

The polycomb group protein EZH2 is involved in progression of prostate cancer.

2002: TRBarrette; AMChinnaiyan; SMDhanasekaran; DGhosh; CKumar-Sinha; APOtte; KJPienta; MARubin; ... MGSanda; RGSewalt; SVarambally; MZhou;

411

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

2004: MCBenson; DBerry; PABurch; EDCrawford; MHHussain; JAJones; MKohli; PNLara; ... CMoinpour; DPPetrylak; DRaghavan; EJSmall; CMTangen; METaplin;

405

Prospective identification of tumorigenic prostate cancer stem cells.

2005: PABerry; ATCollins; CHyde; NJMaitland; MJStower;

397

In vivo cancer targeting and imaging with semiconductor quantum dots.

2004: LWChung; YCui; XGao; RMLevenson; SNie;

390

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24.

2007: DAlbanes; GLAndriole; EECalle; GCancel-Tassin; SJChanock; NChatterjee; OCussenot; PFearnhead; ... HSFeigelson; JFFraumeni; EPGelmann; DSGerhard; EGiovannucci; RBHayes; RHoover; DJHunter; KBJacobs; PKraft; MJMinichiello; NOrr; CRodriguez; FRSchumacher; BJStaats; GThomas; MJThun; MTucker; AValeri; JVirtamo; SWacholder; ZWang; SWeinstein; RWelch; WCWillett; MYeager; KYu;

377

The development of androgen-independent prostate cancer.

2001: BJFeldman; DFeldman;

356

Mortality results from a randomized prostate-cancer screening trial.

2009: PLCO Project Team; GLAndriole; CDBerg; SSBuys; DChia; TRChurch; JDClapp; EDCrawford; ... MNFouad; EPGelmann; JKGohagan; RLGrubb; RBHayes; GIzmirlian; BSKramer; PAKvale; ABMiller; BO'Brien; PFPinsky; PCProrok; JMRathmell; DJReding; TLRiley; JLWeissfeld; LAYokochi;

351